Baseline patient, disease, and transplant characteristics
| Patient characteristics . | Frequency (%) n = 102* . |
|---|---|
| Age | |
| <60 y | 63 (62) |
| ≥60 y | 39 (38) |
| Gender | |
| Female | 40 (39) |
| Male | 62 (61) |
| KPS at transplant* | |
| ≥90 | 69 (69) |
| 70-80 | 31 (31) |
| Stage at diagnosis* | |
| Stage 1/2 | 22 (22) |
| Stage 3/4 | 78 (78) |
| IPI at transplant | |
| >2 | 34 (33) |
| ≤2 | 68 (67) |
| LDH at transplant* | |
| High | 40 (40) |
| Normal | 61 (60) |
| CNS involvement site | |
| Leptomeningeal | 35 (34) |
| Parenchymal | 31 (30) |
| Leptomeningeal and parenchymal | 11 (11) |
| CSF only | 8 (8) |
| Other† | 17 (17) |
| Extent of disease prior to transplant‡ | |
| CNS alone | 24 (24) |
| CNS and systemic | 68 (69) |
| Systemic alone | 7 (7) |
| Prior lines of therapy | |
| ≤2 | 68 (67) |
| >2 | 34 (33) |
| Time from diagnosis to transplant | |
| >18 mo | 49 (48) |
| ≤18 mo | 53 (52) |
| Disease status at transplant | |
| CR/CRu | 76 (75) |
| Not remission | 26 (25) |
| CNS directed therapy before transplant* | |
| MTX-based regimen | 28 (30) |
| ARA-C–based regimen | 21 (23) |
| MTX- and ARA-C–based regimen | 30 (32) |
| Intrathecal alone | 14 (15) |
| Conditioning regimen§ | |
| BEAM +/− rituximab | 54 (53) |
| Thiotepa-based | 25 (24) |
| GBM-based | 18 (18) |
| Other | 5 (5) |
| Patient characteristics . | Frequency (%) n = 102* . |
|---|---|
| Age | |
| <60 y | 63 (62) |
| ≥60 y | 39 (38) |
| Gender | |
| Female | 40 (39) |
| Male | 62 (61) |
| KPS at transplant* | |
| ≥90 | 69 (69) |
| 70-80 | 31 (31) |
| Stage at diagnosis* | |
| Stage 1/2 | 22 (22) |
| Stage 3/4 | 78 (78) |
| IPI at transplant | |
| >2 | 34 (33) |
| ≤2 | 68 (67) |
| LDH at transplant* | |
| High | 40 (40) |
| Normal | 61 (60) |
| CNS involvement site | |
| Leptomeningeal | 35 (34) |
| Parenchymal | 31 (30) |
| Leptomeningeal and parenchymal | 11 (11) |
| CSF only | 8 (8) |
| Other† | 17 (17) |
| Extent of disease prior to transplant‡ | |
| CNS alone | 24 (24) |
| CNS and systemic | 68 (69) |
| Systemic alone | 7 (7) |
| Prior lines of therapy | |
| ≤2 | 68 (67) |
| >2 | 34 (33) |
| Time from diagnosis to transplant | |
| >18 mo | 49 (48) |
| ≤18 mo | 53 (52) |
| Disease status at transplant | |
| CR/CRu | 76 (75) |
| Not remission | 26 (25) |
| CNS directed therapy before transplant* | |
| MTX-based regimen | 28 (30) |
| ARA-C–based regimen | 21 (23) |
| MTX- and ARA-C–based regimen | 30 (32) |
| Intrathecal alone | 14 (15) |
| Conditioning regimen§ | |
| BEAM +/− rituximab | 54 (53) |
| Thiotepa-based | 25 (24) |
| GBM-based | 18 (18) |
| Other | 5 (5) |
ARA-C, cytarabine; CR, complete response; CRu, complete response uncertain; CSF, cerebrospinal fluid; GBM, gemcitabine, busulphan, melphalan; IPI, international prognostic index; KPS, Karnofsky performance scale; MTX, methotrexate.
Numbers do not add up for a total of 102 in some subgroups because of missing information, unless otherwise specified.
Included patients with isolated neurolymphomatosis, intramedullary spinal dissemination, and others not otherwise classified such as epidural with nerve root or spine involvement.
Disease involvement prior to salvage therapy for relapsed patients and at presentation for patients who underwent upfront consolidation with transplant.
BEAM and GBM-based conditioning were given as previously described (references 18,–20). Thiotepa-based regimens included BCNU/thiotepa plus or minus rituximab (n = 17) and thiotepa/busulfan/cyclophosphamide plus or minus rituximab (n = 8). Five patients received “other” less commonly used regimens.